Fulgent Genetics Management

Management Kriterienprüfungen 2/4

Fulgent Genetics CEO ist Ming Hsieh , ernannt in May 2016, hat eine Amtszeit von 8.5 Jahren. Die jährliche Gesamtvergütung beträgt $5.31M , bestehend aus 18.8% Gehalt und 81.2% Boni, einschließlich Aktien und Optionen des Unternehmens. besitzt direkt 28.8% der Aktien des Unternehmens, im Wert von MX$3.92B . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 4.7 Jahre bzw. 3.8 Jahre.

Wichtige Informationen

Ming Hsieh

Geschäftsführender

US$5.3m

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	18.8%
Amtszeit als Geschäftsführer	8.5yrs
Eigentum des Geschäftsführers	28.8%
Durchschnittliche Amtszeit des Managements	4.7yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	3.8yrs

Jüngste Management Updates

Recent updates

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Ming Hsieh im Vergleich zu den Einnahmen von Fulgent Genetics verändert?
Datum	Gesamtvergütung	Gehalt	Unternehmensgewinne
Jun 30 2024	n/a	n/a	-US$163m
Mar 31 2024	n/a	n/a	-US$166m
Dec 31 2023	US$5m	US$1m	-US$168m
Sep 30 2023	n/a	n/a	-US$64m
Jun 30 2023	n/a	n/a	-US$49m
Mar 31 2023	n/a	n/a	-US$26m
Dec 31 2022	US$5m	US$948k	US$143m
Sep 30 2022	n/a	n/a	US$272m
Jun 30 2022	n/a	n/a	US$392m
Mar 31 2022	n/a	n/a	US$461m
Dec 31 2021	US$6m	US$664k	US$507m
Sep 30 2021	n/a	n/a	US$569m
Jun 30 2021	n/a	n/a	US$493m
Mar 31 2021	n/a	n/a	US$417m
Dec 31 2020	US$248k	US$240k	US$214m
Sep 30 2020	n/a	n/a	US$48m
Jun 30 2020	n/a	n/a	US$3m
Mar 31 2020	n/a	n/a	-US$459k
Dec 31 2019	US$240k	US$240k	-US$411k
Sep 30 2019	n/a	n/a	-US$2m
Jun 30 2019	n/a	n/a	-US$4m
Mar 31 2019	n/a	n/a	-US$6m
Dec 31 2018	US$240k	US$240k	-US$6m
Sep 30 2018	n/a	n/a	-US$5m
Jun 30 2018	n/a	n/a	-US$6m
Mar 31 2018	n/a	n/a	-US$5m
Dec 31 2017	US$240k	US$240k	-US$3m

Vergütung im Vergleich zum Markt: MingDie Gesamtvergütung ($USD5.31M) liegt über dem Durchschnitt von Unternehmen ähnlicher Größe auf dem Markt MX ($USD338.05K).

Entschädigung vs. Einkommen: MingDie Bezüge der Mitarbeiter sind gestiegen, während das Unternehmen unrentabel ist.

Geschäftsführer

Ming Hsieh (68 yo)

8.5yrs

Amtszeit

US$5,309,167

Vergütung

Mr. Ming Hsieh has been an Independent Director of Fortinet, Inc. since April 2013. He is the Founder of Fulgent Genetics, Inc. and had been its President until May 2022 & serves as its Chief Executive Off...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Ming Hsieh	Chairman & CEO	8.5yrs	US$5.31m	28.8% MX$ 3.9b
Jian Xie	COO & President	6.6yrs	US$1.79m	1.43% MX$ 194.9m
Paul Kim	Chief Financial Officer	8.8yrs	US$1.78m	0.40% MX$ 55.1m
Hanlin Gao	Chief Scientific Officer & Laboratory Director	8.2yrs	US$1.49m	2.82% MX$ 384.4m
Natalie Prescott	General Counsel & Chief Privacy Officer	2.5yrs	keine Daten	keine Daten
Doreen Ng	VP of Operations & Compliance and GM of Houston Office	4.1yrs	keine Daten	keine Daten
Jakub Sram	Vice President of Business Development & Sales	9.8yrs	keine Daten	keine Daten
Ellen Tsui	Vice President of Human Resources	2.5yrs	keine Daten	keine Daten
Brandon Perthuis	Chief Commercial Officer	4.7yrs	keine Daten	keine Daten
Lawrence Weiss	Chief Medical Officer	3.5yrs	keine Daten	keine Daten
Ray Yin	President & Chief Scientific Officer of Fulgent Pharma	2yrs	keine Daten	keine Daten

4.7yrs

Durchschnittliche Betriebszugehörigkeit

58yo

Durchschnittliches Alter

Erfahrenes Management: FLGT *Das Führungsteam des Unternehmens gilt als erfahren (4.7 Jahre durchschnittliche Betriebszugehörigkeit).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Ming Hsieh	Chairman & CEO	8.5yrs	US$5.31m	28.8% MX$ 3.9b
Regina Groves	Independent Non-Employee Director	1.8yrs	US$625.60k	0.0039% MX$ 534.0k
Linda Marsh	Independent Director	5.3yrs	US$270.50k	0.062% MX$ 8.4m
Michael Nohaile	Independent Non-Employee Director	2.3yrs	US$268.50k	0.0079% MX$ 1.1m

3.8yrs

Durchschnittliche Betriebszugehörigkeit

67yo

Durchschnittliches Alter

Erfahrener Vorstand: FLGT *Die Vorstandsmitglieder gelten als erfahren (3.8 Jahre durchschnittliche Amtszeit).

Fulgent Genetics Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Chief Financial Officer recently sold Mex$729k worth of stock

Chairman & CEO recently sold Mex$1.0m worth of stock

Fulgent Genetics, Inc., Annual General Meeting, May 16, 2024

Chief Financial Officer recently sold Mex$5.8m worth of stock

Chief Financial Officer recently sold Mex$1.0m worth of stock

COO & President recently sold Mex$824k worth of stock

Recent updates

New minor risk - Shareholder dilution

Fulgent Genetics, Inc. to Report Q3, 2024 Results on Nov 08, 2024

Chief Financial Officer recently sold Mex$729k worth of stock

Chairman & CEO recently sold Mex$1.0m worth of stock

Second quarter 2024 earnings released: US$0.29 loss per share (vs US$0.38 loss in 2Q 2023)

Fulgent Genetics, Inc. Revises Earnings Guidance for the Year 2024

Fulgent Genetics, Inc. to Report Q2, 2024 Results on Aug 02, 2024

First quarter 2024 earnings released: US$0.45 loss per share (vs US$0.52 loss in 1Q 2023)

Fulgent Genetics, Inc. to Report Q1, 2024 Results on May 03, 2024

Fulgent Genetics, Inc., Annual General Meeting, May 16, 2024

Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024

Full year 2023 earnings released: US$5.64 loss per share (vs US$4.77 profit in FY 2022)

Fulgent Genetics, Inc. Provides Earnings Guidance for the Year 2024

Fulgent Genetics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Third quarter 2023 earnings released: US$0.44 loss per share (vs US$0.057 profit in 3Q 2022)

Fulgent Genetics, Inc. Announces Two Poster Presentations At SITC 2023 Annual Meeting

Fulgent Genetics, Inc. to Report Q3, 2023 Results on Nov 03, 2023

Chief Financial Officer recently sold Mex$5.8m worth of stock

Chief Financial Officer recently sold Mex$1.0m worth of stock

Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter of 2023 and Full Year 2023

Fulgent Genetics, Inc. Announces Data from a Phase 1/1b Clinical Study of FID-007 in Treating Various Solid Tancers

COO & President recently sold Mex$824k worth of stock

First quarter 2023 earnings released: US$0.52 loss per share (vs US$5.09 profit in 1Q 2022)

Fulgent Genetics, Inc. Provides Earnings Guidance for the Second Quarter of 2023 and Full Year 2023

Less than half of directors are independent

Fulgent Genetics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Fulgent Genetics, Inc. Appoints Reggie Groves to Its Board of Directors

Less than half of directors are independent

COO & President recently sold Mex$457k worth of stock

Less than half of directors are independent

Fulgent Genetics, Inc., Annual General Meeting, May 01, 2023

Fulgent Genetics, Inc. (NasdaqGM:FLGT) acquire Fulgent Pharma Holdings, Inc for approximately $100 million.

Fulgent Genetics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2022

Fulgent Genetics, Inc. Announces Resignation of Leonard Post from the Board and as the Chair of the Nominating and Corporate Governance Committee

The Klein Law Firm Files Class Action Complaint on Behalf of Shareholders of Fulgent Genetics, Inc

Fulgent Genetics, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Less than half of directors are independent

Less than half of directors are independent

Fulgent Genetics, Inc. Announces Resignation of John Bolger from the Board

Pomerantz Law Firm Announces the Filing of A Class Action Against Fulgent Genetics, Inc

Chief Financial Officer recently sold Mex$552k worth of stock

COO & President recently sold Mex$599k worth of stock

Investor sentiment deteriorated over the past week

Chief Financial Officer recently sold Mex$1.9m worth of stock

Fulgent Genetics, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2022

Second quarter 2022 earnings released: EPS: US$0.38 (vs US$2.74 in 2Q 2021)

Fulgent Genetics, Inc. Announces Launch of PCR Based Test to Detect Monkeypox

Investor sentiment improved over the past week

Fulgent Genetics, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Helio Genomics and Fulgent Genetics Announces That American Medical Association Approves A New Category I Cpt® Code for the Helioliver™ Test

COO & President recently sold Mex$719k worth of stock

COO & President recently sold Mex$719k worth of stock

Chief Financial Officer recently sold Mex$1.3m worth of stock

First quarter 2022 earnings released: EPS: US$5.09 (vs US$6.96 in 1Q 2021)

Fulgent Genetics, Inc. Provides Earning Guidance for Second Quarter of 2022

Fulgent Genetics, Inc. Announces Executive Appointments

Fulgent Genetics, Inc. Revises Revenue Guidance for the First Quarter Ended March 31, 2022 and Full Year Ended December 31, 2022

Fulgent Genetics, Inc., Annual General Meeting, May 18, 2022

Chief Financial Officer recently sold Mex$530k worth of stock

Chief Financial Officer recently sold Mex$530k worth of stock

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Fulgent Genetics, Inc. Provides Earning Guidance for the First Quarter and Full Year of 2022

Fulgent Genetics, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Investor sentiment deteriorated over the past week

Chief Financial Officer recently sold Mex$1.1m worth of stock

Investor sentiment deteriorated over the past week

Chief Operating Officer recently sold Mex$1.3m worth of stock

Chief Operating Officer recently sold Mex$2.4m worth of stock

Investor sentiment improved over the past week